Vasanthavada Madhav, serving as the Chief Commercial Officer for Abeona Therapeutics Inc. (NASDAQ: ABEO), has offloaded a portion of his equity stake in the biotechnology firm. According to regulatory disclosures, Madhav sold $51,548 worth of common stock over a two-day period. The transactions were executed specifically to cover tax obligations arising from the vesting of restricted stock awards. On June 8, 2026, Madhav disposed of 4,170 shares at a weighted average price of $5.4295 per share. These shares were liquidated through multiple transactions with prices fluctuating between $5.345 and $5.54. The following day, June 9, 2026, an additional 5,450 shares were sold at a weighted average price of $5.3042 per share, with transaction prices ranging from $5.24 to $5.47. Following these divestments, Madhav retains direct ownership of 303,451 shares of Abeona Therapeutics common stock.
The executive sale coincides with a period of heightened financial activity for Abeona Therapeutics. The company recently reported its first-quarter 2026 earnings, delivering results that exceeded market expectations for both earnings per share (EPS) and revenue. Abeona posted an EPS of -$0.30, surpassing the anticipated -$0.34. Furthermore, the company achieved revenue of $8.72 million, which significantly exceeded the forecast of $4.62 million. Despite these favorable financial outcomes, the company’s stock experienced a decline in pre-market trading immediately following the earnings release. There were no reports of mergers or acquisitions involving Abeona Therapeutics in the current period. Analyst opinions or changes in stock ratings were not mentioned in the latest updates.
Market data indicates that Abeona trades at approximately $5.45, a level below InvestingPro’s Fair Value estimate for the stock. This valuation gap suggests the shares may be undervalued at current levels. InvestingPro analysis notes that the company maintains a strong balance sheet with more cash than debt. The platform offers additional ProTips for ABEO investors, though specific details of these tips are not provided in the disclosure. Analyst consensus remains optimistic, with a Strong Buy rating and price targets ranging from $14 to $28. Current trading activity shows the stock closed at $5.445, up $0.0650 or 1.21%, and traded at $5.49 in after-hours activity, up $0.0400 or 0.73%. The stock chart indicates a range between $5.2 and $5.35 during the trading day. Investors and stakeholders may find these recent developments noteworthy, particularly the divergence between strong operational results and recent insider selling activity.